Thirty jobs to be created in DCU pharmaceutical enterprise
Up to 30 highly-skilled pharmaceutical jobs are to be created in Dublin, it was announced today.
It follows the takeover of an innovative Dublin City University (DCU) start-up enterprise by a major European company.
Archport was set up at the university in 1998 to offer contract production and development services for the biopharmaceutical industry.
German-based Uetikon who has taken an 80% stake in the business said it will provide significant investment, including 30 new bio-processing jobs, as part of an overall expansion scheme.
The company already has purpose-built biopharmaceutical laboratories on the DCU campus. The university is to retain a 20% share in the venture.
Professor Martin Clynes, founder of Archport, said: “This success vindicates the support given by DCU and Bioresearch Ireland in the 1980s to what was then a very new area of research.”
He added: “It also illustrates the important impact that government support for research centres such as National Institute for Cellular Biotechnology can have on economic development.”
Uetikon chief executive officer Dr Heinz Sieger praised DCU for its innovation and world-class biotechnology research.
